<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndrome</z:hpo> and <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> secondary to radiotherapy, radiation exposure, and chemotherapy is a well-documented malignant stem cell disorder </plain></SENT>
<SENT sid="1" pm="."><plain>The incidence and natural course of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> and <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> after organ transplantation remains less thoroughly investigated </plain></SENT>
<SENT sid="2" pm="."><plain>In our institution, 631 heart transplantations have been performed between 1983 and 1998 </plain></SENT>
<SENT sid="3" pm="."><plain>We report five patients (age, 22-63 years) with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) (n=1) or <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) (n=4) occuring 4-8 years after transplantation </plain></SENT>
<SENT sid="4" pm="."><plain>Immunosuppression consisted uniformly of a combination of <z:chebi fb="0" ids="8382">prednisone</z:chebi>, <z:chebi fb="0" ids="4031">cyclosporine</z:chebi>, and <z:chebi fb="2" ids="2948">azathioprine</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>Successful cytogenetic analysis was performed in three patients, showing typical cytogenetic abnormalities in each case </plain></SENT>
<SENT sid="6" pm="."><plain>The course of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> was uniformly fatal </plain></SENT>
<SENT sid="7" pm="."><plain>One patient with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess of blasts according to the FAB criteria, is alive with transfusion dependency 32 months after diagnosis </plain></SENT>
<SENT sid="8" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> may occur during immunosuppression after heart transplantation </plain></SENT>
<SENT sid="9" pm="."><plain>Treatment results are poor in this subgroup of patients with secondary <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
</text></document>